Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effects of exenatide (Byetta) on liver biochemistry, liver histology and lipid metabolism in patients with non-alcoholic fatty liver disease

X
Trial Profile

Effects of exenatide (Byetta) on liver biochemistry, liver histology and lipid metabolism in patients with non-alcoholic fatty liver disease

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Exenatide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Most Recent Events

    • 01 Feb 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 20 Jul 2008 The expected completion date for this trial has been extended from Jun 2009 to Feb 2010 as reported by ClinicalTrials.gov.
    • 20 Jul 2008 Status changed from initiating to recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top